<< Back to News

System Formulary Update
Bevacizumab-bvzr (Zirabev)

Situation

Bevacizumab-bvzr (Zirabev) 25 mg/mL (100 mg/4 mL SDV) and (400 mg/16 mL SDV) for injection was approved for addition to the health system formulary as the preferred bevacizumab biosimilar. This was approved at the June 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medication was reviewed: Bevacizumab-bvzr (Zirabev) 25 mg/mL (100 mg/4 mL SDV) and (400 mg/16 mL SDV) for injection

Assessment/Recommendation

Change effective: Tuesday, July 27^th

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Bevacizumab-bvzr (Zirabev) 25 mg/mL (100 mg/4 mL SDV) and (400 mg/16 mL SDV) for injection

Note: Stock of this formulary product may vary at individual entities